Since it has been suggested that GM3 is involved in the pathophysiological changes associated with obesity and/or metabolic disorders by inhibiting insulin signaling [14, 15], we originally expected that DKO mice, which were unable to produce all gangliosides except GM3 systemically, would exhibit severe metabolic disorders due to insulin dysfunction. Here, INS is linked to metabolic disease.